News
SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...
The company also shared Phase 3 data from the ACHIEVE-1 trial of orforglipron, its oral obesity drug, which met A1C reduction targets and showed dose-dependent weight loss over 40 weeks.
23don MSN
Blockbuster weight-loss shots like Ozempic, Wegovy and Victoza may have an unexpected side effect impacting as many as 47million Americans, a new study from researchers in Italy found.
A target A1C of 7% is a common goal for adults with diabetes, helping reduce long-term complications and improve blood sugar ...
GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...
16h
Verywell Health on MSN10 Common Medications That May Be Disrupting Your Body's Nutrient BalanceSome common medications can lead to vitamin and mineral deficiencies. Learn which drugs can interact in this way.
A new study reports that GLP-1 medications may improve low testosterone in men with obesity or type 2 diabetes. The findings ...
Once-weekly IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.
Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.
Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed about 20% of their body ...
Women with diabetes who were overweight or had obesity lost more weight and had greater odds of diabetes remission when swapping diet soda for water.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results